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Abstract: The roots of Holostemma annularis K. Schum (Asclepiadacae) are used in traditional 
medicine to treat diabetes. This medicinal plant, widely used in more than 34 ayurvedic 
  preparations, was evaluated in a high fructose diet in induced insulin resistance and in C57BL/6J 
ob/ob diabetic mice for its antidiabetic activity. Graded doses of both chloroform and methanolic 
extracts of the roots of H. annularis were administered to normal and experimental diabetic 
rats for 21 days. Serum glucose, triglycerides, cholesterol levels and total protein in urine were 
analyzed. Significant results were observed in the estimated parameters. These data justify the 
use of the plant in the treatment of diabetes mellitus and is a potential source for the isolation 
of new active agents for diabetes mellitus.
Keywords: Holostemma annularis, high fructose diet, antihyperglycemic, C57BL/6J   
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Introduction
Diabetes is associated with sustained high glucose concentrations in the blood beyond a 
certain level that leads to long term damage, dysfunction and failure of various organs 
including eyes, kidney, nerves, heart and blood vessels. Insulin plays a central role in 
the regulation of glucose homeostasis and acts in a coordinated fashion on cellular 
events that include the regulation of ion and amino acid uptake, protein synthesis 
and degradation, gene transcription and mRNA turnover, and cellular growth and 
  differentiation.1,2 An impairment of insulin action (insulin resistance) is involved in 
many diseases, including noninsulin dependent diabetes, obesity, hypertension and 
cardiovascular disease.3 Development of safe antidiabetic agents is still a challenge 
for scientists working in this area. The development of new treatment modalities 
requires animal models that mimic the range of pathophysiogical changes seen in 
diabetic humans.4 The most common is the rat model because of the complications of 
diabetes induced by streptozotocin. However, streptozotocin induces type 1 diabetes 
and experimental results from this model may be relevant only to a small proportion of 
diabetic patients. Type 2 diabetes is associated with complications such as hypertension, 
endothelial damage, cardiac hypertrophy, inflammation, atherosclerosis, ventricular 
contractile dysfunction, fibrosis, retinopathy, neuropathy and nephropathy. Diet-
induced models of type 2 diabetes, rather than the streptozotocin-induced model of 
type 1, may serve as a better vehicle to investigate possible interventions for these 
complications.5 Both human and animal studies have shown that fructose is a highly 
lipogenic nutrient that contributes to insulin resistance, metabolic defects and devel-
opment of a pre-diabetic or diabetic state.6 High fructose diet in rats (60% of the Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 88
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diet) has been used to induce cardiovascular symptoms 
such as hypertension, hypertriglyceridemia, increased 
  collagen deposition in the heart and kidneys associated with 
increased oxidant concentration and decreased antioxidant 
defences.7–9 These features are almost identical to clinical 
type 2 diabetes. Hence high fructose diet-induced diabetes 
in rats is used to evaluate antidiabetic drugs. This study was 
designed to examine the possibility of the antidiabetic effect 
of Holostemma annularis K. Schum (Asclepiadacae) (HA) 
in diabetic C57/BL6J ob/ob mice; which was considered a 
good model for type 2 diabetes as it displays many of the 
characteristics of the human diseases including hyperglyce-
mia, insulin resistance and progressive obesity.10 In humans, 
the occurrence of type 2 (non-insulin dependent) diabetes 
mellitus has been related to a strong genetic influence. In 
mice, the autosomal recessive diabetes (db) mutation results 
in metabolic changes similar to those observed in type 2 
diabetes in humans. The relative diabetes susceptibility 
observed among certain inbred strains carrying either the 
db mutation on chromosome 4, or the obesity (ob) mutation 
on chromosome 6, provides evidence of genetic differences. 
While the nature of this genetic influence is unknown, both 
db/db and ob/ob mice exhibit profound resistance to insulin.11 
There is increasing evidence that indicates that oxidative 
stress produced under hyperglycemia can cause, or lead to, 
insulin resistance and diabetic complications.12 
Moreover, several studies have shown that antioxidants 
ameliorate a number of altered physiological and metabolic 
parameters that occur as a result of type 2 diabetes.13,14 The 
roots of HA, which is reported to have a potent antioxidant 
property15 and used traditionally in Indian system of medicine 
to treat diabetes, was selected to screen for possible antidia-
betic activity in high fructose diet-induced and C57BL/6J 
ob/ob diabetic mice. Also the roots are reported to contain 
β-sitosterol, lupeol, and alpha-amyrin as the main constituents 
which are reported to have both antioxidant and antidiabetic 
properties.16,17 The roots of this plant are also reported to have 
an antidiabetic effect in streptozotocin-induced diabetic rats 
(Type-1).18 However, there is no available evidence of such 
an effect of HA root in type 2 diabetes or an insulin resistant 
animal model. Based on these profiles of HA, work was 
undertaken to screen the roots of the plant for its antidiabetic 
activity in type 2 diabetes.
Material and methods
Preparation of plant extract
Roots of HA were collected from the Herbal Folk Research 
Centre (Reg. No. 37 of 1998) Tirupathi, Andhra Pradesh 
(India). It was authenticated by taxonomist Prof. Vedhavathy, 
and a voucher specimen was deposited in SV University. 
The roots were dried at room temperature, until moisture 
free. Finally, the dried roots were powdered coarsely and 
then passed through a sieve (no. 44) to obtain a uniform 
powder. The coarse powder obtained was extracted with 
petroleum ether to remove any fatty substances; the marc 
was further extracted exhaustively with chloroform and 
methanol separately in a Soxhlet apparatus and filtered. 
Excess solvent was completely removed by using a rotary 
flash evaporator to obtain a chocolate colored semisolid 
extract. The obtained semisolid mass was completely dried 
in mini lyophilizer.
Chemicals and instruments
Streptozotocin was purchased from Cisco Research 
  Laboratories Ltd, (Mumbai, India). Glibenclamide was 
obtained as gift sample from Ranbaxy Laboratories Ltd. 
Fructose, beef extract, sodium chloride, and potassium 
chloride, were purchased from SD Fine Chemicals Ltd, 
(Mumbai). All chemicals used in this study were of analytical 
grade. Auto-Analyzer (Star 21 plus) was used to estimate 
various biochemical parameters using standard procedures. 
A Mini Lyophilizer (LTE Scientific Ltd, UK) and rotary flash 
evaporator were used for preparing extracts.
Animals
Healthy adult male 5- to 6-old Wistar albino rats (180–200 g) 
were used for the high fructose diet model. C57BL/6J mice 
10–14 weeks old and (weighing 50–60 g) were procured 
from the National Institute of Nutrition, Hyderabad and 
used as the diabetic ob/ob mice model. For toxicity evalu-
ation mice were procured from HSK College of Pharmacy. 
Department of Pharmacology (Bagalkot, Karnataka, India). 
The rats and mice were housed in polypropylene cages and 
maintained under suitable nutritional and environmental 
(12-hour light–12-hour dark cycle: 25 ± 3°C and 35%–60% 
humidity) conditions throughout the experiment. All the 
experimental protocols were approved by the institutional 
animals’ ethics committee (HSKCP/IAEC. Clear 2004–05. 
Dated: 27/12/2004), HSK College of Pharmacy, (Bagalkot, 
Karnataka, India).
Toxicity evaluation in mice
The alcohol and chloroform extracts were tested for their 
acute and short term toxicity in mice. To determine acute 
toxicity of a single oral administration of the HA extract, 
different doses (0.5, 1.0, 1.5, 2 g/kg) were administered to Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 89
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different groups of mice (2 mice were used for each group, 
control mice received Tween 80). Mortality and general 
behavior of the animals was observed periodically for 48 
hours. The animals were observed continuously for the initial 
4 hours and intermittently for the next 6 hours and then again 
at 24 hours and 48 hours following drug administration. The 
parameters observed were grooming, hyperactivity, sedation, 
loss of righting reflex, respiratory rate and convulsion. To 
study short term toxicity, 3 groups of mice each containing 
6 male mice (20–25 g, body weight [bw]) were used. Group 
I was kept as control and group II and group III received 200 
and 400 mg/kg of HA extracts in Tween 80. The drug was 
administered daily for 14 days per os (po). The control group 
received 5% Tween 80 in an identical manner. The behavior 
of the animals was observed daily for 1 hour in the forenoon 
for 14 days. Initial and final bw, water and food intake, state 
of stool and body temperature were observed. The animals 
were killed on the 15th day. Hematological and serum bio-
chemical parameters such as hemoglobin content, white 
blood cells (WBC), glutamate pyruvate transaminase (GPT), 
glutamate oxaloacetate transaminase(GOT) and alkaline 
phosphatase(ALP) were determined. Liver, spleen, kidneys 
and brain were dissected and weights of these organs were 
determined. Both extracts did not produce any behavioral 
changes, biochemical changes and mortality up to the dose 
of 3000 mg/kg bw. Hence 1/10th of this dose (high dose) 
was used for the study.19
High fructose diet
The high fructose diet contained fructose (624 g/kg diet), fat 
as vegetable oil (50 g/kg diet), protein (223 g/kg diet) and a 
1:3.6 sodium/potassium ratio. The standard diet contained 
1:3 sodium, potassium rodent chow diet containing vegetable 
starch (527 g/kg diet), fat as vegetable oil (35 g/kg diet), 
animal protein (220 g/kg diet) and a 1:3.3 (3 g Na+/kg diet 
and 10 g K+/kg diet).20
High fructose diet-induced 
diabetic rat model
Male Wistar rats (180–200 g) were randomly divided in to 
7 groups. Group I served as solvent control and received 
the vehicle (2% Tween 80) at 0.5 mL/kg bw and received 
the standard diet. Group II served as positive control and 
received glibenclamide (5 mg/kg bw po), along with the 
high fructose diet. Group III (diabetic control) received the 
high fructose diet alone. Group IV and V received the freshly 
prepared chloroform extract of HA (CEHA) suspension in 
2% Tween 80 at two different dose levels,150 mg/kg and 
300 mg/kg bw po along with high the fructose diet. Group 
VI and VII received the freshly prepared methanol extract 
of HA (MEHA) suspension in 2% Tween 80 at two different 
dose levels, 150 mg/kg and 300 mg/kg bw po along with the 
high fructose diet. The animals were treated for 21 days. The 
animals were kept in metabolic cages and urine was collected 
for estimation of total urine protein. On days 1, 7, 14 and 
21 animals were anesthetized and blood was collected by   
retro-orbital puncture for the assessment of the activity.
C57 BL/6J ob/ob diabetic mice model
Thirty-six diabetic C57BL/6J ob/ob mice 10–14 weeks old 
were randomly divided into six groups. Group I received a 
standard diet for 21 days. Group II served as positive control 
and received glibenclamide (5 mg/kg po), Group III and IV 
received CEHA at two different dose levels, 150 mg/kg and 
300 mg/kg bw po, Group V and VI received MEHA at two 
different dose levels 150 mg/kg and 300 mg/kg bw po. All 
the animals received standard diet along with drug treatment 
for 21 days. On days 1, 10, and 21 animals were anesthetized 
and blood was collected by retro-orbital puncture for bio-
chemical estimation and assessment of activity.
Glucose tolerance test
As described by Babu and colleagues.21
Biochemical analysis
Blood was collected in heparin-coated tubes and centri-
fuged at 3000 rpm for 10 minutes. Serum glucose level was 
  estimated by GOD-POD method21 using a commercial kit 
(Span Diagnostics, India). Serum triglycerides and total 
cholesterol levels were measured according to Allian et al22 
and Friedewald et al.23 Total protein in urine was estimated 
by protein CSF kit using auto-analyzer.
Statistical analysis
The statistical analysis was carried out by one-way analysis 
of variance (ANOVA). The values are means ± standard error 
of mean (SEM). Comparison of mean values of different 
groups treated with different dose levels of extracts and posi-
tive control with normal were estimated by Tukey’s multiple 
comparison test. P values less than 0.05 were considered to 
be statistically significant.
Results
Body weight changes
There was no significant difference in mean bw values 
between the fructose-fed control and HA-treated groups Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 90
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(260 ± 10 g, 258 ± 7 g and 256 ± 8 g, respectively) during 
the 21 days of the experimental period. Similar results were 
observed in the diabetic ob/ob mice model.
Effect of HA extracts in high fructose 
diet-induced change in serum and urine 
biochemical parameters
Fructose feeding significantly increased serum glucose when 
compared to normal rats (188 ± 7.2 mg/dL, P  0.001 [Table 1]). 
Administration of chloroform and methanolic extract of HA 
(150 and 300 mg/kg) along with fructose feeding significantly 
(P  0.001) reduced the serum glucose values in a dose 
dependent manner during 21 days of the experimental study 
when compared to the group fed fructose alone (Table 1). 
Hypertriglyceridemia and hypercholesterolemia are common 
features in animal models of insulin resistance induced by a 
high fructose diet.24,25 Increased levels of triglycerides and 
cholesterol are the main predictors and/or causative agents 
for inducing the insulin resistance in type 2 diabetes. The 
triglyceride and cholesterol levels were significantly higher   
(P  0.001, 153.83 ± 1.7 g/dL, P  0.05, 89.01 ± 7.39 g/dL, 
respectively) in the diabetic control group than in the normal 
animals. In the HA administered group of animals the 
triglyceride (83.33 ± 6.3 g/dL, P  0.001) and cholesterol 
levels (72.60 ± 6.57 g/dL, P  0.05) were significantly lower 
than in the diabetic control group of animals (Table 1). On day 
21 the urine analysis was performed. The total protein in 
the urine of the HA (300 mg/kg)-treated group of animals 
reduced significantly (1.2 ± 0.1 g/dL, P  0.05) (Table 1), 
suggesting partly the nephroprotective activity of the drug. 
Low dose of HA (150 mg/kg) was not significant in showing 
  nephroprotective activity. However the nephroprotective 
effect of HA needs further study. The results of our study 
indicate that the development of hyperglycemia and progres-
sion of diabetes by feeding a high fructose diet and HA might 
be prevented and/or delayed.
Oral glucose tolerance test (OGTT)
The fasting plasma glucose level was elevated in the high 
fructose diet test group when compared to the normal group 
at the end of the 21-day study. After 21 days of dietary 
treatment the OGTT test showed a significant increase of 
plasma glucose levels in the high fructose diet test group 
after 2 hours of glucose challenge compared with the normal 
diet group (Table 3).
Effect of HA extracts in serum 
bio-chemical changes in C57BL/6J mice
Serum glucose levels in diabetic C57BL/6J ob/ob mice after 4 
hours fasting were measured on days 0, 10, and 21 after daily 
Table 1 Effect of chloroform and methanol extracts of Holostemma annularis on high fructose diet induced change in serum glucose, 
triglycerides, and cholesterol and urine total proteins
Group Serum glucose (mg/dL) Serum triglycerides 
(mg/dL)
Total cholesterol 
(mg/dL)
Total protein in   
urine (g/dL)
Day Day Day Day
  1 7 14 21 21 21 21
Normal control 57 ± 6.0 62 ± 4.8 64 ± 3.0 71 ± 1.4 86.34 ± 6.6 70.57 ± 6.40 Nil
Diabetic control  
(5% Tween 80, p.o)
65 ± 2.2 87 ± 3.8 137 ± 6.0 188 ± 7.2*** 153.83 ± 1.7*** 89.01 ± 7.39* 1.9 ± 0.14***
Glibenclamide 
(5 mg/kg, po)
63 ± 3.1 60 ± 2.8 71 ± 5.1 82 ± 2.9*** 99.53 ± 6.1*** 75.45 ± 5.72** 1.1 ± 0.11***
CEHA 
(150 mg/kg)
59 ± 3.1 63 ± 2.8 78 ± 2.6 126 ± 2.9** 114.69 ± 11.1* 80.37 ± 5.90* 1.8 ± 0.13
CEHA 
(300 mg/kg)
49 ± 3.0 75 ± 5.2 103 ± 6.6 96 ± 6.9*** 89.35 ± 6.8*** 74.87 ± 5.55* 1.3 ± 0.09*
MEHA 
(150 mg/kg)
64 ± 4.6 66 ± 6.5 98 ± 6.5 117 ± 7.6** 126.64 ± 6.8* 82.53 ± 5.4* 1.7 ± 0.18
MEHA 
(300 mg/kg)
54 ± 5.4 71 ± 6.5 87 ± 3.8 94 ± 3.4*** 83.33 ± 6.3*** 72.60 ± 6.57* 1.2 ± 0.12*
Notes: Effect of normal (saline), Tween 80 (2%), glibenclamide (5 mg/kg), chloroform extract of Holostemma annularis (CEHA) 150 and 300 mg/kg and methanol extract of 
H. annularis (MEHA) 150 and 300 mg/kg on serum glucose, triglycerides, cholesterol and total protein level in urine in high-fructose diet induced diabetic rats. The results were 
analyzed by Student’s t test and by comparing mean of treatment group, control group with normal. Conclusions are presented as mean ± SEM. P value 0.05 was considered 
as significant. *P  0.05, **P  0.01, ***P  0.001.
Abbreviation: SEM, standard error of mean.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 91
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oral administration of HA or vehicle. As shown in Table 2, 
diabetic ob/ob mice had remarkably high fasting serum glucose 
levels (180 mg/dL), which decreased significantly (P  0.01) 
after administration of high-dose (300 mg/kg) CEHA and 
MEHA (163.5 ± 12.9 and 156.1 ± 13.9 mg/dL, respectively). On 
day 10 serum glucose level were 172.2 ± 12.0 mg/dL (P  0.05) 
compared to the vehicle group, 191.5 ± 9.8 mg/dL. On day 
21, the high-dose group serum glucose level was significantly 
reduced (156.1 ± 13.9 mg/dL) compared to the vehicle 
group (201.6 ± 11.8 mg/dL, P  0.01). At the low dose 
(150 mg/kg), however, the serum glucose decreased from 
191.5 ± 9.8 mg/dL to 171.4 ± 11.2 mg/dL on day 10 and 
164.3 ± 11 mg/dL on day 21 (P  0.05). HA inhibited serum 
glucose level in a dose-dependent manner. The glucose-
lowering effect of CEHA and MEHA were compared to 
glibenclamide which reduced the serum glucose significantly 
(P  0.01). We also evaluated the effects of HA (150 and 
300 mg/kg) on serum triglyceride and cholesterol in ob/ob 
mice. As shown in Table 2, after administration of HA 
high-dose treatment (300 mg/kg), serum triglyceride levels 
  significantly decreased from 68.2 ± 42.2 mg/dL (Day 21) 
to 53.3 ± 11.2 mg/dL (P  0.05) and cholesterol level from     
169 ± 12.4 mg/dL to 121 ± 18.3 mg/dl (P  0.05). In the low-
dose group (150 mg/kg), serum triglyceride and cholesterol 
level were lowered significantly on day 21 (59.4 ± 12.3 mg/dL) 
and 144 ± 15.5 mg/dL, P  0.05 versus vehicle group, respec-
tively. The results showed that HA (150 and 300 mg/kg) 
caused antihypertriglyceridemia and antihypercholesterolemia 
effects after oral administration.
These results suggest that HA suppressed the elevation of 
serum glucose, triglycerides and cholesterol in both models. 
Antihyperlipidemic effect needs further study. The forego-
ing observations lead us to conclude that HA inhibited the 
development of early hyperglycemia and hyperglyceridemia. 
The drug needs a further thorough study to identify the anti-
diabetic mechanism.
Table 2 Effect of chloroform and methanol extracts of Holostemma annularis on serum glucose, triglyceride and cholesterol in C57 
BL/6J mice
Group Serum Glucose 
(mg/dl)
Serum 
Triglyceride 
(mg/dl)
Serum 
Cholesterol 
(mg/dl)
Day Day Day
0 10 21 21 21
C57BL/6J  
diabetic mice
183.3 ± 10.6 191.5 ± 9.8 201.6 ± 11.8 68.2 ± 42.2 169 ± 12.4
Glibenclamide 
(5 mg/kg)
188.5 ± 17.6 169.5 ± 5.8 149.4 ± 10.3** 49.3 ± 38.4** 117 ± 16.4**
CEHA 
(150 mg/kg)
187.6 ± 12.3 171.4 ± 11.2 166.5 ± 10.2* 60.2 ± 10.4* 144 ± 15.5*
CEHA 
(300 mg/kg)
190.0 ± 18.1 178.7 ± 15.1* 163.5 ± 12.9** 56.1 ± 9.7* 121 ± 18.3*
MEHA 
(150 mg/kg)
189.4 ± 13.3 175.4 ± 12.3 164.3 ± 11* 59.4 ± 12.3* 148 ± 17.3*
MEHA 
(300 mg/kg)
195.8 ± 15.9 172.2 ± 12.0* 156.1 ± 13.9** 53.3 ± 11.2* 127 ± 14.7*
Notes: Effect of glibenclamide (5 mg/kg), chloroform extract of Holostemma annularis (CEHA) 150 and 300 mg/kg and methanol extract of H. annularis (MEHA) 150 and 
300 mg/kg on serum glucose, triglycerides and cholesterol level in C57BL/6J ob/ob diabetic mice. The results were analyzed by Student’s t test and by comparing mean 
of treatment group, control group with glibenclamide. Conclusions are presented as mean ± SEM. P value 0.05 was considered as significant. *P  0.05, **P  0.01,   
***P  0.001.
Abbreviation: SEM, standard error of mean.
Table 3 Effect of chloroform and methanol extract of Holostemma 
annularis on glucose tolerance
Treatment Initial Serum glucose 
(mg/100 mL)  
Time (minutes) after  
glucose administration
30 90
Control (Tween 80) 52 ± 5.0 138 ± 2.8 129 ± 4.0
CEHA (150 mg/kg) 55 ± 3.8 114 ± 4.5** 119 ± 5.6**
MEHA (150 mg/kg) 59 ± 4.5 126 ± 5.3** 118 ± 5.2**
Notes: The rats of all groups were loaded with glucose (3 g/kg po) 30 minutes after 
the drug treatment.   Values are mean ±SD. n = 6 in each group. **P  0.001 (compared 
to control value). *P  0.01 (compared to control value).
Abbreviations: SEM, standard error of mean; CEHA, chloroform extract of 
  Holostemma annularis; MEHA, methanol extract of H. annularis.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 92
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Discussion
A high fructose diet induces insulin resistance, alterations 
in lipid metabolism, and oxidative stress in rat tissues.26 
  Fructose is readily absorbed and rapidly metabolized by 
human liver. Westernization of diets has resulted in sig-
nificant increases in added fructose, leading to typical daily 
consumptions amounting to 85–100 g fructose per day. The 
  exposure of the liver to such large quantities of fructose 
leads to rapid stimulation of lipogenesis and triglycerides 
  accumulation; which in turn contributes to reduced insulin 
sensitivity and hepatic insulin resistance/glucose intolerance. 
These negative effects of fructose are the reason that fructose 
metabolism has gained recent research attention.27,28 The 
long-term negative effects can include changes in digestion, 
absorption, plasma hormone levels, appetite, and hepatic 
metabolism, leading to the development of insulin resistance, 
diabetes, obesity, and inevitably cardiovascular disease.29 
Because of its lipogenic properties, excess fructose in the diet 
can cause glucose and fructose malabsorption, together with 
greater elevations in triglycerides and cholesterol compared 
to other carbohydrates.30 In the liver, fructose is metabolized 
into glyceraldehyde and dihydroxyacetone phosphate. These 
particular fructose end products can are readily taken up in 
the glycolytic pathway. Of key importance is the ability of 
fructose to bypass the main regulatory step of glycolysis; 
the conversion of glucose-6-phosphate to fructose 1,   
6-bisphosphate, controlled by phosphofructokinase. Thus, 
while glucose metabolism is negatively regulated by 
  phosphofructokinase, fructose can continuously enter the 
  glycolytic pathway. Therefore, fructose can uncontrollably 
produce glucose, glycogen, lactate, and pyruvate, provid-
ing both the glycerol and acyl portions of acyl-glycerol 
molecules. These particular substrates, and the resultant 
excess energy flux due to unregulated fructose metabolism, 
will promote the overproduction of triglycerides.31,32 A high 
fructose diet can have hypertriglyceridemic and pro-oxidant 
effects, and fructose-fed rats have shown less protection 
from lipid peroxidation.33 Oxidative stress has often been 
implicated in the pathology of insulin resistance induced by 
fructose feeding, and lipid peroxides, and reactive substances 
are undeniably elevated in fructose-fed animals, especially 
accompanying a deficient antioxidant system.34 Administra-
tion of HA has been shown to prevent these changes, and 
improve insulin sensitivity.18 In our study, treatment with HA 
also prevented several deleterious effects of fructose feed-
ing; such as the increases in serum glucose, cholesterol and 
triglyceride levels. In the other model the antihyperglycemic 
effects of HA root were evaluated in diabetic C57BL/6J ob/
ob mice. Diabetes and obesity are complex genetic diseases 
caused by a combination of genetic predisposition and 
environmental exposure.35,36 The genetic contribution can be 
either monogenic or polygenic, with polygenic inheritance 
being the predominant mode of inheritance in human type 2 
diabetes and obesity. The leptin mutations arose spontane-
ously in the C57BL/6J mice, and resulted in the severe 
early-onset of obesity, hyperphagia, hyperinsulinemia, and 
insulin resistance with modest hyperglycemia.37 Leptin 
deficiency is associated with dyslipidemia (abnormal levels 
of cholesterol and triglycerides in the blood) and insulin 
resistance, a precursor to diabetes in animals and humans 
with lipoatrophy (fat loss).38
HA has been documented as a traditional treatment for 
diabetes. In the present study, CEHA and MEHA (150 mg/kg 
and 300 mg/kg) significantly decreased the serum glucose, 
triglycerides and cholesterol in the high fructose-induced 
diabetic rats and in the diabetic C57BL/6J ob/ob mice. 
It also rendered nephroprotection by decreasing the total 
protein levels in urine. The alcoholic root extract of HA has 
been shown to have a potential antioxidant activity in both 
in vitro and in vivo models.15 However there is no evidence 
of any scientific studies into its antidiabetic activity. The 
chemical investigation of the root extract of HA revealed 
the presence of β-sitosterol, lupeol, α-amyrin and amino 
acids.39 The presence of β-sitosterol, lupeol supports its 
antioxidant potential.40,41 The HA root has been reported to 
have chemoprotective activity in cyclophosphamide-induced 
toxicity.42 Many studies have validated the role of β-sitosterol 
and lupeol in the management of diabetes and hypercholes-
terolemia.17,41 β-sitosterol has been shown to normalize blood 
sugar and insulin levels in type 2 diabetics. The mechanism 
for this effect is that β-sitosterol stimulates the release of 
insulin in the presence of non-stimulatory glucose concen-
trations,43 and inhibits glucose-6-phosphatase.44 β-sitosterol 
reduces elevated blood glucose levels by the downregulation 
of glucose-6-phosphatase. Human liver microsome studies 
show that β-sitosterol inhibits cholesterol absorption.45 In a 
clinical study β-sitosterol was shown to lower cholesterol 
and triglyceride levels.46 These results indicate a possible 
antihyperglycemic use for β-sitosterol in the prevention and 
treatment of diabetes. In addition to this the other antioxidant 
constituent of HA, lupeol, also supports antidiabetic activity. 
Lupeol present in the roots of HA has the ability to protect 
cells and tissues from oxidative stress, which induces the 
formation of cytoprotective enzymes like catalase and super-
oxide dismutase.47 Furthermore, the treatment of chloroform 
and methanolic extracts of HA root showed an improved Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 93
Antidiabetic activity of Holostemma annularis  Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
lipid profile by reducing the level of total cholesterol and 
triglycerides. Plant sterols (β sitosterol) found in the root 
may have contributed to the improvement in lipid profile. 
Plant sterols along with lupeol were well known for their 
  antihypercholestemia by lowering the cholesterol level.41,48–51 
This antihyperlipidemic effect could represent a protective 
mechanism against the development of hypercholestemia 
complications associated with diabetes. CEHA and MEHA 
decreased the serum glucose, cholesterol and triglyceride 
levels of the diabetic C57BL/6J mice, suggesting an antihy-
perglycemic effect. The principal antioxidant compounds 
(sitosterols and lupeol) of HA root may also be responsible 
for hypoglycemic effects shown in this study.
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